Compare PHIN & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PHIN | HCM |
|---|---|---|
| Founded | 2023 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.4B |
| IPO Year | N/A | N/A |
| Metric | PHIN | HCM |
|---|---|---|
| Price | $68.52 | $15.08 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 5 | 1 |
| Target Price | ★ $60.80 | $13.75 |
| AVG Volume (30 Days) | ★ 441.8K | 46.4K |
| Earning Date | 02-12-2026 | 08-07-2025 |
| Dividend Yield | ★ 1.56% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.18 | 0.53 |
| Revenue | ★ $3,427,000,000.00 | $602,197,000.00 |
| Revenue This Year | $3.03 | N/A |
| Revenue Next Year | $1.40 | $15.54 |
| P/E Ratio | $31.78 | ★ $5.46 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $36.25 | $11.51 |
| 52 Week High | $70.03 | $19.50 |
| Indicator | PHIN | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 75.56 | 67.64 |
| Support Level | $64.74 | $14.63 |
| Resistance Level | $70.03 | $15.26 |
| Average True Range (ATR) | 1.61 | 0.40 |
| MACD | 0.36 | 0.22 |
| Stochastic Oscillator | 83.84 | 94.37 |
Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, the company generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.